b Carbapenem-resistant Acinetobacter baumannii is increasing in prevalence. Polymyxin B and tigecycline are among the most active antibiotics used against this pathogen in vitro. Past in vitro studies, however, neglected the importance of simulating exposures observed in humans to determine their antibacterial effects. In this study, four carbapenem-resistant A. baumannii isolates were evaluated using an in vitro pharmacodynamic model. Free-drug exposures using 1 mg/kg of body weight of polymyxin B every 12 h (q12h), 100 and 200 mg tigecycline q12h, and the combination of these regimens were simulated. The microbiological responses to these treatments were measured by the change in log 10 CFU/ml over 24 h and the area under the bacterial killing and regrowth curve (AUBC). Resistance was assessed by a population analysis profile (PAP) conducted after 24 h of treatment. Polymyxin B achieved a reduction on the order of ؊2.05 ؎ 0.68 log 10 CFU/ml against these A. baumannii isolates, while all isolates grew to control levels with tigecycline monotherapy. Combination therapy with polymyxin B plus 200 mg tigecycline q12h achieved a greater reduction in bacterial density than did therapy with polymyxin B alone (؊3.31 ؎ 0.71 versus ؊2.05 ؎ 0.68 log 10 CFU/ml, P < 0.001) but not significantly different than combination therapy with 100 mg tigecycline q12h (؊2.45 ؎ 1.00 log 10 CFU/ml, P ‫؍‬ 0.370). Likewise, combination therapy with polymyxin B plus 200 mg tigecycline q12h significantly reduced the AUBC compared to that with polymyxin B alone (62.8 ؎ 8.9 versus 79.4 ؎ 10.5 log 10 CFU/ml, P < 0.05). No changes in the PAP from baseline were observed for either antibiotic alone. In this study, combination therapy with simulated exposures of polymyxin B and tigecycline at an aggressive dose of 200 mg q12h produced synergistic or additive effects on humans against these multidrug-resistant A. baumannii strains.
T
he emergence and spread of multidrug-resistant Acinetobacter baumannii are of great concern in hospitals across the globe. A. baumannii can cause a range of infections, from complicated skin and soft tissue wounds to bloodstream infections and ventilatorassociated pneumonia (1) (2) (3) . Considered one of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, A. baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) by the Infectious Diseases Society of America, A. baumannii is particularly problematic due to its ability to carry numerous resistance mechanisms, resulting in a sparse availability of antibiotics that retain activity against this pathogen (4) . Consequently, clinical outcomes as a result of these infections are typically poor, presumably due to lack of appropriate antibiotic therapy (5-7).
Carbapenem antibiotics have previously been considered the gold standard treatment option for infections caused by A. baumannii (1) . However, due to the global emergence of serine-and metallo-␤-lactamase-producing strains (8, 9) , carbapenem susceptibility has substantially declined. Between 2002 and 2008, carbapenem resistance increased from 20% to nearly 50% across the United States (10) . In other global regions, such as the Asia-Pacific, carbapenem resistance has also increased to approximately 50%, largely due to the presence of class D serine carbapenemases, including bla and bla OXA-58 (11) . As a result of this increasing carbapenem resistance, alternative antibiotic classes have become part of treatment amalgamations, often alongside carbapenems. Of these alternative classes, the polymyxin antibiotics (polymyxin B and colistin) and tigecycline remain the most active treatments in vitro against multidrug-resistant A. baumannii (12) (13) (14) .
Combination antibiotic therapy is often employed for the treatment of serious A. baumannii infections, with the intent of patients benefiting from a synergistic interaction between two or more antibiotics (1) . Most synergy studies against A. baumannii, however, are conducted in vitro by applying time-kill or checkerboard methodology, where only specific fixed concentrations of antibiotics are studied. Using this methodology, numerous studies have observed synergistic interactions between polymyxins and various other antibiotic classes, including carbapenems, tigecycline, rifampin, and most recently, vancomycin (15) (16) (17) (18) (19) (20) (21) (22) . These time-kill and checkerboard experiments, however, ignore the contribution of human pharmacokinetics and the dynamic effects of varied drug concentrations over the duration of the experiment. The purpose of the current study was to simulate human exposures using polymyxin B and tigecycline, alone and in combination, against carbapenem-resistant A. baumannii to assess if a more clinically applicable synergistic interaction is present using these agents. Simulated drug exposures. Polymyxin B and tigecycline were administered as a bolus into the model to simulate free-drug exposures achieved in human blood serum. Polymyxin B was simulated with a dosing regimen of 1 mg/kg of body weight every 12 h, based on pharmacokinetics from critically ill patients (24) . Protein binding was assumed to be 86%, and the target free-drug peak concentration (fC peak ) and half-life were 1.16 g/ml and 3.2 h, respectively, resulting in a target free-drug area under the concentration curve over the 12-h dosing interval (fAUC 0 -12 ) of 4.8 g · h/ml (24) . Tigecycline was simulated with higher doses of 100 mg every 12 h and 200 mg every 12 h based on data from a murine pneumonia infection model, in which it was observed that the fAUC/MIC ratio was the pharmacodynamic parameter of importance predicting tigecycline efficacy against A. baumannii, and dosing regimens of Ն200 mg daily were required to achieve a 1-to 2-log reduction in organism density (25) . Tigecycline pharmacokinetics were extrapolated from a study of patients infected with community-or hospital-acquired pneumonia (26) and used to simulate steady-state fAUC 0-12 exposures of 2.3 and 4.6 g · h/ml, as previously described (27) . The targeted fC peak values were 0.6 g/ml and 1.2 g/ml for the 100-mg and 200-mg dosages, respectively, and protein binding was assumed to be 70%. Due to the prolonged half-life of tigecycline, the concentration time profile was simulated as a rapidly declining distributional phase over the first 2 h, followed by a slow elimination thereafter to achieve the target AUC exposure (27) .
MATERIALS AND METHODS
In vitro pharmacodynamic model. A one-compartment chemostat in vitro model was used for all experiments (28) . Briefly, each experiment consisted of three independent models (two experimental treatment models and one growth control model), which ran simultaneously for each isolate. The models were placed in a 37°C circulating water bath for optimal temperature control. The experiments were performed at a bacterial density of 10 6 CFU/ml for 24 h against all A. baumannii strains. Three independent starting inocula of 10 6 CFU/ml were set up from an overnight culture of the test isolate for all model experiments. Cationadjusted Mueller-Hinton broth (CAMHB) (Becton, Dickinson and Company, Sparks, MD) was used as the bacterial growth medium for all experiments with A. baumannii. The antibiotic was administered 0.5 h after the inoculation of the bacteria into the models and then 12 h later. Fresh broth was supplied via a peristaltic pump (Masterflex L S model 7524-40; ColeParmer Instrument Company) set to achieve the intended exposures.
To assess bacterial density over time, samples were obtained from each model and serially diluted in normal saline. Aliquots of the diluted samples were plated for quantitative culture. Trypticase soy agar plates (100-mm diameter) with 5% sheep blood were used for quantitative determinations. The colony counts were read after 18 to 24 h of incubation at 37°C. The lower limit of detection for bacterial density was 1.7 log 10 CFU/ml. To evaluate the antibiotic activity response of each dosing regimen, bacterial density was measured by the change in log 10 CFU/ml from 0 h to 24 h (i.e., log change ϭ log 10 CFU 24 Ϫ log 10 CFU 0 ). Synergy was defined as a reduction of Ն2 log 10 CFU/ml for the combination than for its most active component at 24 h (29) . Additivity was defined as a 1-to Ͻ2-log 10 CFU/ml reduction for the combination. Antagonism was defined as a Ͼ2-log 10 CFU/ml increase for the combination, and no interaction was defined as a Ͻ1-log 10 CFU/ml decrease to a 2-log 10 CFU/ml increase for the combination. Additionally, time-kill curves were constructed and the area under the bacterial killing and regrowth curve (AUBC) was calculated to compare antibiotic efficacy measures (30) .
Antibiotic concentration and exposure determinations. The samples of CAMHB taken from each of the treatment models were assayed for polymyxin B at 0, 6, 12, 18, and 24 h and for tigecycline at 0, 2, 12, 14, and 24 h. All samples were immediately stored at Ϫ80°C until analysis. The concentrations of the polymyxin B1 and B2 components were assayed using a liquid chromatography tandem mass spectrometer (LC-MS/MS) at the Eurofins Global Central Laboratory (Chantilly, VA, USA). The intraday quality control samples at 144, 960, and 1,600 ng/ml had coefficients of variation (CVs) of 7.2 to 14.9% for B1 and 5.9 to 15.5% for B2. The concentrations for B1 and B2 at each time point were summed during the analyses of polymyxin B exposure. Tigecycline was analyzed by a validated high-performance liquid chromatography (HPLC) method at the Center for Anti-Infective Research and Development, as described previously (31) . The tigecycline assay was linear (r ϭ 0.996 to 0.999) over a concentration range of 0.05 to 5 g/ml. The intraday quality control samples at 0.2 and 4 g/ml had CVs of 5.0% and 2.1%, respectively. The interday quality control samples at 0.2 and 4 g/ml had CVs of 4.8% and 3.2%, respectively.
Emergence of resistance. An analysis of the heteroresistant subpopulations of bacteria by population analysis profiles (PAPs) was conducted at 24 h by plating 10 to 100 l of the treatment and control compartments or its serial saline dilution on Muller-Hinton agar plates with various concentrations of each antibiotic (0, 1, 3, 4, 8, and 20 g/ml for polymyxin B and 0, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, and 20 g/ml for tigecycline). The colonies were counted after 48 h of incubation at 35°C. The lower limit of detection was 1.7 log 10 CFU/ml.
Statistical analyses. The mean log 10 CFU/ml reductions using polymyxin B monotherapy, tigecycline monotherapy, and combination therapy at 24 h from the starting inoculum (0 h), as well as the AUBC for each therapy, were compared using one-way analysis of variance and the Holm-Sidak method for multiple comparisons (SigmaPlot for Windows, version 2012; Systat Software, Inc.). A P value of Ͻ0.05 was considered significant.
RESULTS

Pharmacokinetic exposures.
The achieved polymyxin B fAUC 0 -12 exposures (i.e., polymyxin B1 plus B2) were 4.22 Ϯ 0.84 g · h/ml across all experiments, which was similar to the targeted exposure of 4.8 g · h/ml. The resulting AUC was a result of the lower fC peak of 0.93 Ϯ 0.18 g/ml (compared with target of 1.16 g/ml) and a half-life of 3.6 Ϯ 0.9 h (compared with target of 3.2 h). The fAUC 0 -12 exposure achieved for the 100-mg tigecycline dosage was 3.02 Ϯ 0.24 g · h/ml, which was 31% higher than the target. The fAUC 0 -12 exposure achieved for the 200-mg tigecycline dosage was 4.37 Ϯ 0.45 g · h/ml, which was similar to the targeted exposure of 4.6 g · h/ml. The achieved fC peak values were 0.55 Ϯ 0.13 and 1.19 Ϯ 0.11 g/ml for the 100-mg and 200-mg doses, respectively. Antimicrobial activity. The average bacterial density of the starting inoculum was 6.06 Ϯ 0.09 log 10 CFU/ml across all A. baumannii isolates, and the control isolates grew to 7.33 Ϯ 0.10 log 10 CFU/ml over 24 h in the models, with an AUBC of 173.1 Ϯ 3.3 log 10 CFU · h/ml. Figure 1A to D summarizes the time-kill curves for the polymyxin B and tigecycline regimens alone and in combination against each isolate. The mean changes in bacterial density at 24 h and AUBC against each of the 4 isolates are provided in Tables 2 and 3 , respectively. At 24 h, the combination of 200 mg polymyxin B with tigecycline every 12 h (q12h) achieved significantly greater reductions in CFU/ml than all monotherapy regimens (P Ͻ 0.001); the reduction using this regimen was also significantly greater than the combination of 100 mg polymyxin B with tigecycline q12h (P ϭ 0.049). The combination of 200 mg polymyxin B plus tigecycline q12h was synergistic against A. baumannii isolate 31 and additive against isolates 32 and 35; no interaction was observed against isolate 33. The combination of 100 mg polymyxin B plus tigecycline q12h was additive against isolate 31, with no interaction observed against the remaining isolates. Based on the AUBC endpoints, the combination of 100 mg or 200 mg polymyxin B with tigecycline q12h achieved significantly greater AUBC reductions than that achieved with all other regimens (P Ͻ 0.05).
Emergence of resistance. There were no differences in the PAP results between polymyxin B and tigecycline monotherapy and between combination therapy regimens versus control isolates. No resistant subpopulations grew in the presence of polymyxin B at concentrations of Ͼ1 g/ml. No resistant subpopulations grew in the presence of tigecycline at concentrations above the baseline MIC.
DISCUSSION
Multidrug-resistant A. baumannii is increasingly emerging as a cause of nosocomial infections worldwide. In the absence of newer antibiotics to treat infections caused by this organism, combina- tion antimicrobial therapy with at least one agent being a member of the polymyxin class (polymyxin B or colistin) has become a common treatment strategy (32) . The specific antibiotics that are often combined with polymyxin B against A. baumannii include carbapenems, rifampin, and tigecycline. Because the latter also retains microbiological activity against many multidrug-resistant isolates, the combination of polymyxin B and tigecycline for A. baumannii infections is a popular treatment option. The data supporting these combination regimens are commonly derived from in vitro synergistic studies that employ time-kill or checkerboard methodology. Although useful for identifying the potential for synergistic activity, these experiments are conducted with fixed concentrations of antibiotics, which are unrealistic exposures in humans.
In this pharmacodynamic experiment, we sought to determine if the addition of human simulated exposures of tigecycline at two aggressive dosage regimens added significant antimicrobial activity to polymyxin B at a typical dose of 1 mg/kg q12h. Against 4 clinical carbapenem-resistant A. baumannii isolates, only the addition of the highest tigecycline dosage regimen (i.e., 200 mg every 12 h) significantly added to the activity of polymyxin B using both the 24-h change in log 10 CFU · h/ml and AUBC reduction as endpoints (Tables 2 and 3 ). This combination was synergistic against 1 of the isolates, additive against 2 of them, and indifferent (i.e., no interaction) against 1 isolate. The addition of an exposure consistent with 100 mg tigecycline every 12 h significantly impacted the AUBC but not the 24-h change in log 10 CFU · h/ml. This combination did not display synergy against any of the isolates, was additive against one isolate, and was indifferent against the remaining 3 isolates.
Our observations are in contrast to the time-kill and checkerboard studies using polymyxin B (or colistin) and tigecycline combinations. Across various in vitro studies, the combination of a polymyxin antibiotic and tigecycline at fixed concentrations often resulted in synergy or additivity against A. baumannii isolates (15, 16, 18-21, 33, 34) . These studies combined concentrations of drugs at 0.5 to 4ϫ the MIC, which ranged from 0.5 to 8 g/ml for polymyxin B and tigecycline. Of note, the free-drug concentrations simulated for humans in our experiment targeted a free peak of polymyxin B at approximately 1 g/ml, which declined to 0.08 g/ml by 12 h and a had an fAUC 0 -12 of 4.22 g · h/ml; these concentrations are much lower than those used in these in vitro time-kill and checkerboard synergy experiments. Furthermore, the free-drug peak concentrations of the aggressive tigecycline regimens were 0.55 and 1.19 g/ml for the 100-mg and 200-mg regimens, respectively; these are also much lower than in previous synergy studies. Therefore, it should be not surprising that consistent synergy was not observed against these A. baumannii isolates. Using a rat pneumonia model, Mutlu Yilmaz and colleagues (35) demonstrated that although in vitro synergy was detected for the a The bacterial density for each isolate is the mean of 2 to 4 independent time-kill experiments. All dosages were administered q12h. b The data are presented as the mean Ϯ standard deviation of all time-kill curves (2 to 4 per isolate). Positive values indicate growth from the bacterial density at 0 h, while negative numbers indicate reductions in CFU/ml from 0 h. The results for all groups are significantly different (P Ͻ 0.001), except for 100 mg tigecycline q12h, which did not differ from 200 mg tigecycline q12h (P ϭ 0.695) and 1 mg/kg polymyxin B, which did not differ from 100 mg polymyxin B plus tigecycline q12h (P ϭ 0.370). a AUBC, area under the bacterial killing and regrowth curve. The AUBC for each isolate is the mean of 2 to 4 independent time-kill experiments. All dosages were administered q12h.
b The data are presented as the mean Ϯ standard deviation AUBC of all time-kill curves (2 to 4 per isolate). The results for all groups are significantly different (P Ͻ 0.05), except for the control, which did not differ from 100 mg tigecycline q12h (P ϭ 0.221) and 100 mg polymyxin B plus tigecycline q12h, which did not differ from 200 mg polymyxin B plus tigecycline q12h (P ϭ 0.231).
combination of colistin and tigecycline against a single multidrugresistant A. baumannii isolate, there was no significant difference in the bacterial counts in lung tissue with the combination (35) . This further highlights the importance of taking human simulated drug exposures into consideration and simulating free-drug profiles when making comparative assessments in vitro.
Our observations from the monotherapy experiments suggest that polymyxin B provided the majority of antibacterial effect against these A. baumannii isolates, and when administered alone, tigecycline did not achieve any notable kill. Exposures that resembled aggressive tigecycline dosing regimens were selected in this study based on murine pneumonia model data suggesting that a minimal dose of 200 mg daily was required to achieve fAUC/MIC exposures of 2.17 and 8.78 for 1-and 2-log CFU reductions, respectively (25). For our regimen of 100 mg every 12 h, the achieved fAUC/MIC ratio was approximately 6.04 against isolates 31 and 32 (tigecycline MIC, 1 g/ml) and 1.51 against isolates 33 and 35 (MIC, 4 g/ml), with minimal effects against any of the isolates (Fig. 1A to D) . With the highest tigecycline dosage (200 mg every 12 h), the achieved fAUC/MIC ratio was approximately 2.2 to 8.7, depending on the isolate MIC. Although this regimen achieved significantly greater antibacterial effect based on the AUBC than the regimen of 100 mg every 12 h against the two isolates with MICs of 1 g/ml, regrowth was still apparent by the end of the 24-h experiment; furthermore, no antibacterial effect was observed against the isolates with MICs of 4 g/ml. Since the fAUC/ MIC exposures needed for 1-and 2-log CFU reductions at 24 h were derived using a pneumonia model, it is possible that the tigecycline exposure in the murine lung was greater than in blood and therefore our simulation of free-drug blood concentrations was not sufficient.
In our experiment, a simulated polymyxin B dosage regimen of 1 mg/kg every 12 h achieved rapid bactericidal activity against all 4 polymyxin B-susceptible A. baumannii isolates, resulting in reductions of Ͼ3 log 10 CFU/ml by 4 h (Fig. 1A to D) . After 4 h, the isolates began to regrow until 12 h, when polymyxin B was redosed, followed by another decrease, albeit blunted, in CFU and then slow regrowth again. Like tigecycline, the pharmacodynamic parameter associated with the bactericidal activity of colistin is the fAUC/MIC ratio (36) . Assuming that polymyxin B and colistin have similar pharmacodynamic profiles, an fAUC/MIC ratio of 10 to 20 is required to achieve 1 log 10 kill over 24 h in the thigh and lung infection models, respectively. Our simulated fAUC/MIC exposures were approximately 8 against all 4 isolates, which resulted in a reduction on the order of Ϫ2.05 Ϯ 0.68 log 10 CFU/ml at 24 h. However, the final slopes of 3 out of the 4 isolates suggest that isolates were regrowing, so our observations are not completely discordant with the reported pharmacodynamic targets. The polymyxin B dosing regimen we selected was based on the most frequent dosage used in one of the first pharmacokinetic studies of polymyxin B in 8 patients by Zavascki and colleagues (24) , in which 4/8 patients received 1 mg/kg of polymyxin B every 12 h. A larger more recent study by the same group (37) observed similar polymyxin B dosages that ranged from 0.48 to 3.38 mg/kg/day, most commonly divided into two doses. The fraction unbound of polymyxin B in the larger study, however, was 0.42 compared with 0.14, the latter of which was identified in the earlier trial and used for our simulated free-drug concentrations. As a result, the mean (Ϯ the standard deviation [SD]) daily free AUC for polymyxin B in the patient study was 29.2 Ϯ 12 g · h/ml, about 3.5 times higher than the exposure we simulated in our in vitro study. We speculate that the antimicrobial activity of polymyxin B would increase further in vitro if higher exposures were simulated over the 24-h period; however, additional experiments are needed to determine if a greater polymyxin effect would diminish the synergistic or additive interactions observed with the higher-dose tigecycline regimen in this study.
Polymyxin B heteroresistance was not observed for any of the isolates in this study. This is consistent with another recent in vitro experiment testing colistin in combination with rifampin against A. baumannii (38) . At the lower inoculum tested (10 6 CFU/ml), heteroresistance was not observed until 48 h. This was reduced to 6 h using a higher starting inoculum of 10 8 CFU/ml. It is possible that heteroresistance in our experiment would have been observed at a higher inoculum or if the experiment duration were extended. Therefore, it is not possible at this time to discern if the addition of tigecycline at any dosage regimen is able to prevent the emergence of polymyxin B resistance. No tigecycline resistance or heteroresistance was observed against these 4 A. baumannii isolates.
In conclusion, human simulated exposures of polymyxin B and tigecycline achieved synergistic or additive activity against 3 out of the 4 multidrug-resistant A. baumannii isolates, but only when polymyxin B was combined with the more aggressive tigecycline regimen of 200 mg every 12 h. Our study highlights the importance of considering human simulated exposure effects during in vitro combination therapy studies. Experiments for longer durations and at higher inocula are warranted to determine if this combination regimen provides consistent synergistic interactions.
